These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 24141009)

  • 61. Clonogenic potential and phenotypic analysis of CD34+ cells mobilized by different chemotherapy regimens.
    Cesana C; Regazzi E; Garau D; Caramatti C; Mangoni L; Rizzoli V
    Haematologica; 1999 Sep; 84(9):771-8. PubMed ID: 10477448
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Cyclophosphamide plus etoposide is a safe and effective mobilization regimen in patients with multiple myeloma.
    Heider M; Grass S; Dill V; Rämisch S; Winter C; Verbeek M; Götze KS; Bassermann F; Jilg S
    Transfus Apher Sci; 2021 Oct; 60(5):103197. PubMed ID: 34175195
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Mobilization of peripheral blood stem cells with mitoxantrone and high-dose cytarabine chemotherapy and rhG-CSF in patients with hematopoietic malignancies].
    Qiu HY; Wu DP; Sun AN; Chang WR; Jin ZM; Miao M; Tang XW; Shen YM; Fu ZZ
    Zhonghua Xue Ye Xue Za Zhi; 2004 Aug; 25(8):462-5. PubMed ID: 15555260
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study.
    de la Rubia J; Bladé J; Lahuerta JJ; Ribera JM; Martínez R; Alegre A; García-Laraña J; Fernández P; Sureda A; de Arriba F; Carrera D; Besalduch J; García Boyero R; Palomera Bernal L; Hernández MT; García PR; Pérez-Calvo J; Alcalá A; Casado LF; San Miguel J
    Haematologica; 2006 May; 91(5):621-7. PubMed ID: 16627253
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Blood graft lymphocyte subsets after plerixafor injection in non-Hodgkin's lymphoma patients mobilizing poorly with chemotherapy plus granulocyte-colony-stimulating factor.
    Varmavuo V; Mäntymaa P; Kuittinen T; Nousiainen T; Jantunen E
    Transfusion; 2012 Aug; 52(8):1785-91. PubMed ID: 22304442
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Autologous peripheral blood stem cell mobilization following dose-adjusted cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy alone or in combination with rituximab in treating high-risk non-Hodgkin's lymphoma.
    Shi Y; Zhou P; Han X; He X; Zhou S; Liu P; Yang J; Zhang C; Gui L; Qin Y; Yang S; Zhao L; Yao J; Zhang S
    Chin J Cancer; 2015 Sep; 34(11):522-30. PubMed ID: 26370464
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Mobilization of peripheral-blood progenitor cells with high-dose etoposide and granulocyte colony-stimulating factor in patients with breast cancer, non-Hodgkin's lymphoma, and Hodgkin's disease.
    Copelan EA; Ceselski SK; Ezzone SA; Lasky LC; Penza SL; Bechtel TP; Klein JL; Hehmeyer DM; Scholl MD; Marshall DD; Elder PJ; Risley GL; Avalos BR
    J Clin Oncol; 1997 Feb; 15(2):759-65. PubMed ID: 9053502
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Improved Prediction of CD34+ Cell Yield before Peripheral Blood Hematopoietic Progenitor Cell Collection Using a Modified Target Value-Tailored Approach.
    Sheppard D; Tay J; Palmer D; Xenocostas A; Doulaverakis C; Huebsch L; McDiarmid S; Tinmouth A; Mallick R; Martin L; Birch P; Hamelin L; Allan D; Bredeson C
    Biol Blood Marrow Transplant; 2016 Apr; 22(4):763-767. PubMed ID: 26643030
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Cyclophosphamide plus granulocyte-colony stimulating factor for hematopoietic stem cell mobilization in patients with multiple myeloma.
    Lin TL; Wang PN; Kuo MC; Hung YH; Chang H; Tang TC
    J Clin Apher; 2016 Oct; 31(5):423-8. PubMed ID: 26340986
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Optimal autologous peripheral blood progenitor cell mobilization involves more than the CD34+yield.
    Fasan O
    Biol Blood Marrow Transplant; 2014 Jan; 20(1):2-3. PubMed ID: 24240016
    [No Abstract]   [Full Text] [Related]  

  • 71. A randomized trial of two doses of cyclophosphamide with etoposide and G-CSF for mobilization of peripheral blood stem cells in 318 patients with stage II-III breast cancer.
    Schwartzberg LS; Weaver CH; Birch R; Manner C; Tauer K; Beeker T; Morgan-Ihrig C; MacAneny B; Leff R; Smith R; Hainsworth J; Greco T; Schwerkoske J; Murphy MN; Buckner CD
    J Hematother; 1998 Apr; 7(2):141-50. PubMed ID: 9597571
    [TBL] [Abstract][Full Text] [Related]  

  • 72. CHOP versus CHOP plus ESHAP and high-dose therapy with autologous peripheral blood progenitor cell transplantation for high-intermediate-risk and high-risk aggressive non-Hodgkin's lymphoma.
    Intragumtornchai T; Prayoonwiwat W; Numbenjapon T; Assawametha N; O'Charoen R; Swasdikul D
    Clin Lymphoma; 2000 Dec; 1(3):219-25. PubMed ID: 11707834
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Differential mobilization of CD34+ cells and lymphoma cells in non-Hodgkin's lymphoma patients mobilized with different growth factors.
    Gazitt Y; Shaughnessy P; Liu Q
    J Hematother Stem Cell Res; 2001 Feb; 10(1):167-76. PubMed ID: 11276370
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Peripheral blood CD34+ cell monitoring after cyclophosphamide and granulocyte-colony-stimulating factor: an algorithm for the pre-emptive use of plerixafor.
    Farina L; Spina F; Guidetti A; Longoni P; Ravagnani F; Dodero A; Montefusco V; Carlo-Stella C; Corradini P
    Leuk Lymphoma; 2014 Feb; 55(2):331-6. PubMed ID: 23656194
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Mobilization of peripheral blood progenitor cells following CHOP treatment combined with delayed granulocyte colony-stimulating factor administration in patients with non-Hodgkin's lymphoma.
    Takano H; Sawada K; Sato N; Natoya A; Tarumi T; Hirayama S; Koizumi K; Takahashi TA; Sekiguchi S; Koike T
    Leuk Lymphoma; 1996 May; 21(5-6):473-8. PubMed ID: 9172813
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Factors associated with successful mobilization of progenitor hematopoietic stem cells among patients with lymphoid malignancies.
    Ameen RM; Alshemmari SH; Alqallaf D
    Clin Lymphoma Myeloma; 2008 Apr; 8(2):106-10. PubMed ID: 18501104
    [TBL] [Abstract][Full Text] [Related]  

  • 77. First-line treatment with brief-duration chemotherapy plus rituximab in elderly patients with intermediate-grade non-Hodgkin's lymphoma: phase II trial.
    Hainsworth JD; Litchy S; Lamb MR; Rodriguez GI; Scroggin C; Greco FA
    Clin Lymphoma; 2003 Jun; 4(1):36-42. PubMed ID: 12837153
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Peripheral blood stem cells mobilization in patients with relapsed or refractory lymphomas: A single-center experience.
    Halacoglu A; Serefhanoglu S
    J Cancer Res Ther; 2024 Apr; 20(3):904-908. PubMed ID: 38102912
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Etoposide-mediated interleukin-8 secretion from bone marrow stromal cells induces hematopoietic stem cell mobilization.
    Kang KW; Lee SJ; Kim JH; Lee BH; Kim SJ; Park Y; Kim BS
    BMC Cancer; 2020 Jul; 20(1):619. PubMed ID: 32615949
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Collection of hematopoietic stem cells after previous radioimmunotherapy is feasible and does not impair engraftment after autologous stem cell transplantation in follicular lymphoma.
    Derenzini E; Stefoni V; Maglie R; Casadei B; Pellegrini C; Broccoli A; Stefani G; Fanti S; Motta MR; Narducci R; Argnani L; Zinzani PL
    Biol Blood Marrow Transplant; 2013 Dec; 19(12):1695-701. PubMed ID: 24055654
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.